Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Anticipates up to $10.4M in Net Proceeds from Public Offering

NEW YORK (GenomeWeb News) – CombiMatrix said today that it anticipates up to $10.4 million in net proceeds from a public offering of its securities.

In an amended Form S-1 filed with the US Securities and Exchange Commission, the company said that it intends to offer 10,000 shares of Series D preferred stock and warrants to purchase up to a little more than 4.1 million shares of common stock. The proposed offering also includes about 4.1 million shares of common stock underlying the Series D preferred stock and 4.1 million shares of common stock issuable upon exercise of the warrants.

Ladenburg Thalmann is the underwriter on the offering, which was originally disclosed by CombiMatrix in September. The company has granted the underwriter a 45-day option to purchase up to 1,500 additional shares of Series D preferred stock at a price per share equal to the public offering price of a unit and/or additional warrants to purchase as much as $617,284 of shares to cover any overallotments.

If the overallotment option is exercised, net proceeds would be about $10.4 million, the company said, adding the proceeds will be used to fund general corporate purposes.

CombiMatrix has not yet priced the units in the offering.

The Irvine, Calif.-based company said last week that revenues in its third quarter had risen 15 percent year over year to $1.5 million.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.